Circulation Journal · 2014 · 37 citations · 30 references
MedicineCardiologyCardiopulmonary RehabilitationExercise PhysiologyExercise TestingCardiopulmonary Exercise TestingCardiorespiratory FitnessExercise Prescription For Cardiac PatientsHeart FailureMaximal Oxygen Uptake MeasurementMaximal Oxygen Uptake TestingOxygen Uptake RatePatient Effort AssessmentPatient Effort MeasurementPatient Effort MonitoringPrognostic IndicesVentricular Ejection Fraction Assessment
BACKGROUND: Peak oxygen uptake (V̇O2) and ventilatory efficiency (V̇E/V̇CO2slope) measured on cardiopulmonary exercise testing (CPX) are prognostic indicators in heart failure (HF) patients, but peak V̇O2is influenced by patient effort. In CPX targeting a peak respiratory exchange ratio (pRER; an objective index of effort adequacy) higher than the commonly recommended level, we assessed the safety and prognostic value of CPX parameters compared with non-CPX parameters. METHODS AND RESULTS: We studied 283 consecutive HF patients with left ventricular ejection fraction (LVEF) ≤45% (mean, 26.3%) who underwent CPX targeting pRER >1.20. The attained pRER (mean, 1.26) was consistently high irrespective of LVEF, and there was no major exercise-related adverse event. The composite of all-cause death or HF hospitalization occurred in 111 patients (39%) during a median follow-up of 47 months. Among well-known prognostic markers, peak V̇O2was the most powerful predictor of outcome as both a continuous and an optimal dichotomous variable, followed by V̇E/V̇CO2slope. On multivariate analysis, peak V̇O2was a significant independent predictor, whereas V̇E/V̇CO2slope, B-type natriuretic peptide, and LVEF were not. CONCLUSIONS: In CPX targeting pRER >1.20 for HF patients, peak V̇O2is the most powerful among well-known predictors, without an increased risk of exercise-related events. These findings advocate a high target pRER in CPX even in advanced HF.
30
Eplerenone in Patients with Systolic Heart Failure and Mild Symptoms
Faı̈ez Zannad, John J.V. McMurray, Henry Krum et al. · New England Journal of Medicine · 2010 · 3.1K citations · Full text
Ivabradine and outcomes in chronic heart failure (SHIFT): a randomised placebo-controlled study
Karl Swedberg, Michel Komajda, Michael Böhm et al. · The Lancet · 2010 · 2.6K citations · Full text
Medicine, Cardiology, Pharmacology +11
Efficacy and Safety of Exercise Training in Patients With Chronic Heart Failure
Christopher M. O’Connor, David J. Whellan, Kerry L. Lee et al. · JAMA · 2009 · 2.2K citations · Full text